NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it will release its third quarter 2016 financial results before the open of the market on Tuesday, October 25, 2016. Tarek Sherif, chief executive officer, and Rouven Bergmann, chief financial officer, will also hold a conference call at 8:00 a.m. ET for investors and analysts to discuss the Company’s results and business outlook.
To participate by telephone, domestic participants may dial 1-877-303-2528 and international participants may dial 1-847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register.
Participants can also join the call via a simultaneous live audio webcast, which will be made available on the “Investor” section of Medidata’s website, http://investor.mdsol.com.
A replay of the conference call can be accessed through November 8, 2016, by dialing 1-800-585-8367 domestically or 1-404-537-3406 internationally, with the passcode 91173550. An archive of the call will also be hosted on the “Investor” section of Medidata’s website, http://investor.mdsol.com, for a limited period of time.
Medidata is reinventing global drug development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including more than 700 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.